ARIA ARIAD Pharmaceuticals, Inc.

23.69
+0  (0%)
Previous Close 23.69
Open 23.69
Price To book 0.00
Market Cap 4.60B
Shares 194,200,000
Volume 14,657,842
Short Ratio 6.38
Av. Daily Volume 6,542,560

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

To be acquired by Takeda. Deal to close by the end of February 2017.
To be acquired

Latest News

  1. ARIAD SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of ARIAD Pharmaceuticals, Inc. (ARIA) Over the Proposed Sale of the Company to Takeda Pharmaceutical Company Limited
  2. These 3 Stocks Quadrupled in Just 1 Year
  3. ArQule (ARQL) Catches Eye: Stock Moves 7.2% Higher
  4. ARIAD: Acquisition by Takeda Bodes Well, Competition a Risk
  5. SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of ARIAD Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information
  6. Ariad Pharm downgraded by SunTrust
  7. Former Ariad CEO Berger says Takeda deal was 'merely a matter of time'
  8. ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material D
  9. Ariad Pharmaceuticals Cash Acquisition by Takeda Pharmaceuticals Could a Second Buyer Surface
  10. Takeda deal results in a huge windfall for former Ariad CEO Harvey Berger
  11. After ARIAD's Acquisition, These 3 Cancer Drug Stocks Could Be Next
  12. 4 Stocks in Focus as Biotech M&A Hopes Surge on Takeda-ARIAD Deal
  13. ARIAD Pharma Stock Gains on Acquisition Deal with Takeda
  14. Takeda Takes the Hard Road
  15. Takeda Pharmaceutical Company Limited -- Moody's reviews Takeda Pharmaceutical's ratings for downgrade
  16. Japan's Takeda ready for fresh acquisitions after $5.2 billion Ariad deal
  17. Japan's Takeda ready for fresh acquisitions after $5.2 billion Ariad deal
  18. Japan's Takeda ready for fresh acquisitions after $5.2 bln Ariad deal